Actuate Therapeutics’ (NASDAQ:ACTU) Quiet Period To End Tomorrow

Actuate Therapeutics’ (NASDAQ:ACTU) quiet period is set to end on Monday, September 23rd. Actuate Therapeutics had issued 2,800,000 shares in its public offering on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. During Actuate Therapeutics’ quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Actuate Therapeutics Stock Performance

ACTU opened at $7.31 on Friday. Actuate Therapeutics has a fifty-two week low of $7.01 and a fifty-two week high of $10.16. The stock has a market cap of $139.69 million and a P/E ratio of 48.73.

Insiders Place Their Bets

In other news, major shareholder Leslie W. Kreis sold 24,999 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $9.00, for a total value of $224,991.00. Following the completion of the transaction, the insider now directly owns 131,248 shares of the company’s stock, valued at $1,181,232. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Equity Cof Lp Bios acquired 500,000 shares of the stock in a transaction on Wednesday, August 14th. The shares were acquired at an average price of $8.00 per share, with a total value of $4,000,000.00. Following the completion of the transaction, the director now owns 1,259,427 shares in the company, valued at approximately $10,075,416. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Leslie W. Kreis sold 24,999 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $9.00, for a total transaction of $224,991.00. Following the transaction, the insider now directly owns 131,248 shares of the company’s stock, valued at $1,181,232. The disclosure for this sale can be found here. Insiders own 19.90% of the company’s stock.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.